Product Name
DNAH11, siRNA
Full Product Name
DNAH11 siRNA (Human)
Product Synonym Names
Dynein heavy chain 11. axonemal; Axonemal beta dynein heavy chain 11; Ciliary dynein heavy chain 11
Product Gene Name
DNAH11 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q96DT5
Specificity
DNAH11 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DNAH11 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DNAH11 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DNAH11 sirna
siRNA to inhibit DNAH11 expression using RNA interference
Applications Tested/Suitable for DNAH11 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DNAH11. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001264044.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001277115.1
[Other Products]
UniProt Primary Accession #
Q96DT5
[Other Products]
UniProt Secondary Accession #
Q9UJ82[Other Products]
UniProt Related Accession #
Q96DT5[Other Products]
Molecular Weight
520,369 Da
NCBI Official Full Name
dynein heavy chain 11, axonemal
NCBI Official Synonym Full Names
dynein, axonemal, heavy chain 11
NCBI Official Symbol
DNAH11??[Similar Products]
NCBI Official Synonym Symbols
CILD7; DNHBL; DPL11; DNAHBL; DNAHC11
??[Similar Products]
NCBI Protein Information
dynein heavy chain 11, axonemal
UniProt Protein Name
Dynein heavy chain 11, axonemal
UniProt Synonym Protein Names
Axonemal beta dynein heavy chain 11; Ciliary dynein heavy chain 11
UniProt Gene Name
DNAH11??[Similar Products]
UniProt Entry Name
DYH11_HUMAN
NCBI Summary for DNAH11
This gene encodes a ciliary outer dynein arm protein and is a member of the dynein heavy chain family. It is a microtubule-dependent motor ATPase and has been reported to be involved in the movement of respiratory cilia. Mutations in this gene have been implicated in causing Kartagener Syndrome (a combination of situs inversus totalis and Primary Ciliary Dyskinesia (PCD), also called Immotile Cilia Syndrome 1 (ICS1)) and male sterility. [provided by RefSeq, Mar 2013]
UniProt Comments for DNAH11
DNAH11: Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Defects in DNAH11 are a cause of Kartagener syndrome (KTGS). KTGS is an autosomal recessive disorder characterized by the association of primary ciliary dyskinesia with situs inversus. Clinical features include recurrent respiratory infections, bronchiectasis, infertility, and lateral transposition of the viscera of the thorax and abdomen. The situs inversus is most often total, although it can be partial in some cases (isolated dextrocardia or isolated transposition of abdominal viscera). Defects in DNAH11 are the cause of primary ciliary dyskinesia type 7 (CILD7). CILD is an autosomal recessive disorder characterized by axonemal abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit situs inversus, due to dysfunction of monocilia at the embryonic node and randomization of left-right body asymmetry. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. Belongs to the dynein heavy chain family.
Protein type: Motor; Motility/polarity/chemotaxis; Microtubule-binding
Chromosomal Location of Human Ortholog: 7p21
Cellular Component: dynein complex; microtubule; cytoplasm; cilium
Molecular Function: ATPase activity; microtubule motor activity; ATP binding
Biological Process: metabolic process
Disease: Ciliary Dyskinesia, Primary, 7
Research Articles on DNAH11
1. Mutations in DNAH11 are a common cause of PCD in patients without ciliary ultrastructural defects; thus, genetic analysis can be used to ascertain the diagnosis of PCD in this challenging group of patients.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
